(Q43199221)

English

Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice

scientific article published on 6 January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

0 references

Herman Waldmann

object named as

Herman Waldmann

3

0 references

author name string

Devangi S Mehta

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rudy A Christmas

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Michael Rosenzweig

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

6 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

130

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

103-113

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2009.03217.X

21 January 2018

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

CD3-specific antibodies: a portal to the treatment of autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

CD3-specific antibody-induced active tolerance: from bench to bedside

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855798

29 September 2018

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

1 reference

https://pubmed.ncbi.nlm.nih.gov/20059577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/20059577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20059577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb

1 reference

https://pubmed.ncbi.nlm.nih.gov/20059577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A humanized monovalent CD3 antibody which can activate homologous complement

1 reference

https://pubmed.ncbi.nlm.nih.gov/20059577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20059577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2567.2009.03217.X

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43199221&oldid=1983636263"